Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications

• Type: Another Publication in an International Scientific Journal
• Date: 2020

Authors

Brandao, A (Author) Other; Paulo, P (Author) Other; Manuel R Teixeira (Author) ICBAS

Journal

Title: International Journal Of Molecular Sciences

Vol. 21 No. 7

Pages: 1-23

ISSN: 1661-6596

Publisher: MDPI

Indexing

ISI Web of Knowledge - 14 Citations

Scopus - 14 Citations

Other information

Authenticus ID: P-00S-H01

DOI: 10.3390/ijms21145036

Abstract (EN): Prostate cancer (PrCa) ranks among the top five cancers for both incidence and mortality worldwide. A significant proportion of PrCa susceptibility has been attributed to inherited predisposition, with 10-20% of cases expected to occur in a hereditary/familial context. Advances in DNA sequencing technologies have uncovered several moderate- to high-penetrance PrCa susceptibility genes, most of which have previously been related to known hereditary cancer syndromes, namely the hereditary breast and ovarian cancer (BRCA1, BRCA2, ATM, CHEK2, and PALB2) and Lynch syndrome (MLH1, MSH2, MSH6, and PMS2) genes. Additional candidate genes have also been suggested, but further evidence is needed to include them in routine genetic testing. Recommendations based on clinical features, family history, and ethnicity have been established for more cost-efficient genetic testing of patients and families who may be at an increased risk of developing PrCa. The identification of alterations in PrCa predisposing genes may help to inform screening strategies, as well as treatment options, in the metastatic setting. This review provides an overview of the genetic basis underlying hereditary predisposition to PrCa, the current genetic screening recommendations, and the implications for clinical management of the disease.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 24